Wenn THC auf den menschlichen Körper trifft und ein eigenartiges Kribbeln, entspannte Muskeln und ein verändertes Zeitgefühl produziert, dann liegt das nicht an irgendeiner merkwürdigen Laune der Evolution. Es liegt daran, dass Cannabis die Schlüssel zu einem System nutzt, das unser Körper schon längst entwickelt hatte, bevor ein Mensch jemals eine Hanfpflanze berührt hat. Dieses System heißt Endocannabinoid-System – abgekürzt ECS – und es ist eines der faszinierendsten und vielschichtigsten Regulationsnetzwerke, die die Biologie je hervorgebracht hat. Kaum ein zweites physiologisches System beeinflusst gleichzeitig so viele grundlegende Prozesse: Schmerz, Stimmung, Hunger, Schlaf, Immunabwehr, Gedächtnis und Fortpflanzung. Und kaum ein System wurde so lange übersehen.
📑 Inhaltsverzeichnis
- What is the Endocannabinoid System?
- CB1 and CB2 – Cannabinoid Receptors in Detail
- Anandamide and 2-AG: The Body’s Own Messenger Substances
- Retrograde Signaling: When Neurons Speak Backwards
- How THC and CBD Intervene in the Endocannabinoid System
- The ECS and Its Role in Health and Disease
- Clinical Endocannabinoid Deficiency: When the System Falls Out of Balance
- The ECS as a Therapeutic Target of Modern Medicine
- Frequently Asked Questions About the Endocannabinoid System
- 💬 Fragen? Frag den Hanf-Buddy!
Erst in den späten 1980er und frühen 1990er Jahren entdeckten Wissenschaftler das ECS – paradoxerweise auf der Suche danach, warum THC überhaupt wirkt. Was sie fanden, war weit mehr als ein Erklärungsmodell für das Rauschgefühl. Sie stießen auf ein universelles Kommunikationssystem, das tief in die Funktionsweise fast jedes Organs eingebettet ist und das der Körper seit Jahrmillionen für sich selbst betreibt – mit körpereigenen Cannabinoiden, eigenen Rezeptoren und spezifischen Abbauenzymen. Dieser Artikel erklärt, wie dieses System aufgebaut ist, was es leistet und warum ein Verständnis des ECS für jeden relevant ist, der sich ernsthaft mit Cannabis, Medizin oder Gesundheit beschäftigt.
What is the Endocannabinoid System?
The endocannabinoid system is a part of the nervous system and consists of three basic elements: cannabinoid receptors, endocannabinoids—the body’s own cannabinoids—and the enzymes that produce and break down these messenger substances. Together, these three components form a highly dynamic network that is constantly active and communicates with countless other systems throughout the body.
The term „endocannabinoid“ combines „endo“ (Greek for „inside“) with „cannabinoid“—referring to internal substances that are structurally and functionally similar to cannabinoids from the hemp plant. The name is somewhat misleading, as the system was not named after Cannabis because Cannabis invented it—but rather because researchers used the plant cannabinoid THC as a key to find the corresponding lock in the human body. The lock was always there. It was just waiting for its natural key.
The basic function of the ECS can be summarized in a single word: homeostasis. The term describes the state of internal balance that living organisms must actively maintain. Body temperature, blood sugar levels, hormone concentrations—all these parameters fluctuate constantly, and the ECS helps keep them within a physiologically acceptable range. In short, it is a master regulator. When something in the body falls out of balance, the ECS steps in and counteracts it.
The discovery of this system began in 1988, when neuroscientist Allyn Howlett at Saint Louis University first identified CB1 receptors in rat brains. In 1993, the description of the CB2 receptor followed. The actual endocannabinoids—the body’s own ligands for these receptors—were identified shortly thereafter: anandamide in 1992 and 2-Arachidonoylglycerol (2-AG) in 1995. Within just a few years, it became clear that this was a fundamental biological system that medicine had simply overlooked until then.
CB1 and CB2 – Cannabinoid Receptors in Detail
The ECS communicates via two main receptor types, referred to as CB1 and CB2. Both belong to the family of G-protein-coupled receptors—one of the largest and evolutionarily oldest receptor families. When an endocannabinoid or phytocannabinoid like THC binds to such a receptor, a complex signal cascade is triggered inside the cell, ultimately altering cell behavior.
CB1 receptors are extraordinarily densely distributed throughout the central nervous system and are among the most common G-protein-coupled receptors in the brain. Particularly high concentrations are found in the cerebellum (responsible for motor control and coordination), the basal ganglia (movement control), the hippocampus (memory and learning), and the amygdala (emotional processing). This distribution explains why cannabis simultaneously affects motor control, clouds short-term memory, can reduce anxiety, and changes emotional mood—all these effects stem from CB1 activation in different brain regions. However, CB1 receptors are also present in the peripheral nervous system, in fat tissue, liver, muscles, and the gastrointestinal tract.
CB2 receptors follow a different distribution logic. They are primarily found on immune system cells—B cells, NK cells, mast cells, and macrophages—as well as on bone-building osteoblasts and bone-resorbing osteoclasts. In the healthy brain, CB2 receptors are significantly less common than CB1, but their density increases considerably during inflammatory processes and neurological diseases, suggesting an important role in neuroprotective and immunomodulatory processes. Activation of CB2 receptors does not produce a psychoactive high—it primarily regulates inflammatory responses, immune reactions, and bone metabolism.
Beyond CB1 and CB2, endocannabinoids also interact with other receptors, including the TRPV1 channel (known as the „capsaicin receptor“), GPR55, and GPR119. The complete picture of the ECS is therefore more complex than the simple CB1-CB2 dichotomy—and science continues to discover new interactions.
Anandamide and 2-AG: The Body’s Own Messenger Substances
The best-known endocannabinoids are anandamide (arachidonylethanolamide, abbreviated AEA) and 2-arachidonoylglycerol (2-AG). Both are produced „on demand“—not stored in reserve, but synthesized precisely when the body needs them. This demand-driven production fundamentally distinguishes endocannabinoids from classical neurotransmitters like serotonin or dopamine.
Anandamide was named after the Sanskrit word „Ananda,“ which means bliss or inner joy. The naming is no accident: anandamide binds primarily to CB1 receptors and influences mood, anxiety regulation, sleep, and pain perception. It is a lipophilic molecule that is rapidly broken down enzymatically—primarily by the enzyme fatty acid amide hydrolase (FAAH). The short half-life of anandamide explains why a „natural high“—such as the sense of well-being after intense exercise, which was long attributed to endorphins—is briefer and gentler than a THC-induced high. The structurally related molecule PEA (palmitoylethanolamide) is another endocannabinoid-like lipid that plays an important anti-inflammatory role in the body’s own system.
2-AG is the more abundant endocannabinoid in the brain and binds with high affinity to both CB1 and CB2 receptors. It plays a central role in modulating immune reactions, in neuroprotective protection of nerve cells, and in retrograde signaling between neurons. 2-AG is broken down primarily by the enzyme monoacylglycerol lipase (MAGL). Inhibitors of this enzyme are the subject of intense pharmacological research because they can increase 2-AG concentration in the body without directly interfering with receptor binding.
Retrograde Signaling: When Neurons Speak Backwards
One of the most remarkable properties of the endocannabinoid system is its capacity for retrograde signaling. In the classical model of neurobiology, nerve cells communicate in one direction: the presynaptic cell releases a neurotransmitter, which crosses the synaptic gap and binds to receptors on the postsynaptic cell. The signal travels forward—from the sending cell to the receiving cell.
Endocannabinoids work in exactly the opposite way. When the postsynaptic cell is strongly activated, it produces anandamide or 2-AG, which then travels backward across the synaptic gap to the presynaptic cell and binds to CB1 receptors there. The result: the presynaptic cell reduces its neurotransmitter release. This mechanism serves as an elegant dampening system—the receiving cell essentially tells the sending cell: „I’m overwhelmed, please reduce the signal.“ In this way, the ECS prevents neuronal overstimulation and protects the nervous system from a state of chronic overexcitation.
This retrograde function also explains why the ECS plays such an important dampening role in stress, trauma, and anxiety. A well-functioning endocannabinoid system is, in a sense, a natural buffer against life’s storms. As current research shows, chronic alcohol or substance use can permanently destabilize this system—with far-reaching consequences for emotion regulation and stress management.
How THC and CBD Intervene in the Endocannabinoid System
No discussion of the endocannabinoid system would be complete without examining THC and CBD—the two most prominent cannabinoids from the hemp plant. Both interact with the ECS, but in fundamentally different ways.
THC (tetrahydrocannabinol) is a partial agonist at CB1 and CB2 receptors. Structurally, it resembles the body’s own anandamide, but it is significantly more lipophilic and therefore much more stable. While anandamide is rapidly broken down by FAAH after binding, THC remains active in the receptor much longer and produces stronger and more prolonged receptor stimulation. The result is the well-known psychoactive high: altered time perception, heightened sensory perception, euphoria, but also—at high doses or in vulnerable individuals—anxiety and paranoia. The fact that THC activates the same receptors that the ECS uses for its everyday regulatory work explains why cannabis affects so many physiological processes simultaneously. Further information on the detailed pharmacology can be found in our article on the pharmacodynamics of the hemp plant.
CBD (cannabidiol) works in a completely different way. It has relatively low direct binding affinity for CB1 and CB2. Instead, it functions as a negative allosteric modulator at the CB1 receptor: it alters the receptor structure so that THC binds there less effectively—which explains why CBD can dampen the psychoactive effects of THC. At the same time, CBD inhibits the FAAH enzyme and thus indirectly increases anandamide levels in the body. More anandamide means more activation of the body’s own ECS—without direct external intervention in the receptors. Additionally, CBD interacts with serotonin receptors, the TRPV1 channel, and various other target molecules, which explains its broad pharmacological effects. CBD thus influences the ECS primarily by modulating the body’s own processes—not through direct receptor binding like THC.
The ECS and Its Role in Health and Disease
The endocannabinoid system regulates an impressive spectrum of physiological processes. Pain perception and modulation are among them: CB1 receptors on peripheral nociceptors—pain receptors—and in the spinal cord help determine how strongly pain signals are processed. Patients who receive medical cannabis for pain therapy ultimately benefit from this mechanism. The ECS also influences the sleep-wake rhythm: anandamide rises in the evening hours and prepares the body for sleep, while current studies show how a disrupted ECS can contribute to chronic sleep problems. Appetite regulation, immune modulation, mood stabilization, memory consolidation, and even bone density are all controlled in part by the ECS.
Particularly fascinating is the role of the ECS in inflammatory processes. CB2 receptors on immune cells dampen the release of proinflammatory cytokines when activated—messenger substances that drive inflammation. This mechanism makes the ECS a natural counterweight to excessive immune reactions, such as those occurring in autoimmune diseases, chronic inflammation, or neurodegenerative processes. The respiratory system also benefits: research on asthma shows that endocannabinoids can modulate airway inflammation and influence the smooth muscle of the bronchi.
The fact that the ECS regulates so many things simultaneously has an important consequence: disruptions of this system can manifest in very different disease patterns. Conversely, it also means that cannabis—when properly used—can be helpful in various conditions simultaneously without that being a sign of ineffectiveness or lack of specificity. It is the language in which cannabis speaks to the body. And the body has understood it for millions of years.
Clinical Endocannabinoid Deficiency: When the System Falls Out of Balance
Neuroscientist Ethan Russo coined the concept of „Clinical Endocannabinoid Deficiency Syndrome“ (CEDS) in 2016—clinical endocannabinoid deficiency. The hypothesis: certain chronic diseases that are difficult to treat and where classical therapies often fail might be at least partly attributable to insufficient ECS function. As candidates for this syndrome, Russo primarily identifies migraine, irritable bowel syndrome, and fibromyalgia—three conditions that are all linked by heightened pain sensitivity, autonomic dysregulation, and high rates of psychiatric comorbidity.
The idea is not abstract: there is evidence that patients with migraines have lower anandamide levels in their cerebrospinal fluid than healthy control subjects. Similar findings have been described in fibromyalgia. If the ECS does not function adequately—whether due to genetic variants in enzyme genes, chronic stress, or unhealthy lifestyle—the body has more difficulty maintaining homeostasis. Phytocannabinoids from the hemp plant could serve as exogenous substitutes in such cases and support a deficient endogenous system. A deeper insight into the concept of clinical endocannabinoid deficiency can be found in this article.
CEDS is not yet an established diagnosis, but the concept has spurred research. It motivates viewing the ECS not merely as a biochemical curiosity, but as a clinically relevant target system for preventive and therapeutic strategies. Diet, exercise, stress, and sleep influence ECS activity—factors that should be considered part of the foundation of any health strategy anyway.
The ECS as a Therapeutic Target of Modern Medicine
Scientific attention to the endocannabinoid system has increased exponentially in recent years. The interest in plant cannabis as a medicine is not the only driver of this development—it is above all the fundamental understanding that the ECS represents an extraordinarily promising pharmacological target that extends far beyond the use of THC or CBD. Researchers worldwide are developing substances that specifically modulate individual components of the system: enzyme inhibitors that slow the breakdown of anandamide, allosteric modulators that fine-tune receptor sensitivity, and selective CB2 agonists that inhibit inflammation without producing psychoactive side effects.
Research into neurodegenerative diseases appears particularly promising. In Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, altered ECS parameters have been described—increased CB2 receptor density in inflamed brain tissue, altered endocannabinoid levels, and disrupted enzyme patterns. The question of whether these changes are the cause or consequence of neurodegeneration has not yet been definitively answered. What is clear, however, is that the ECS is involved in these processes and could be specifically targeted in the future to slow the progression of such diseases.
The area of psychiatric disorders is also coming into focus. Depression, post-traumatic stress disorder, and anxiety disorders show in numerous studies a close connection to ECS function. Anandamide levels and CB1 receptor density are frequently altered in depressed patients. CBD, which increases the body’s own anandamide concentration, is already being investigated in clinical trials as an anti-anxiety substance—without the addiction potential or sedation of classical anxiolytics. This makes the ECS one of the most discussed approaches in psychiatry in the coming years.
All these developments underscore why solid foundational knowledge about the endocannabinoid system is relevant for everyone who uses, prescribes, or seriously discusses cannabis medically. This is not a niche topic. This is a central chapter of human biology—one that was long overlooked and is now being caught up on at an accelerating pace.
Frequently Asked Questions About the Endocannabinoid System
What does the endocannabinoid system do?
The endocannabinoid system (ECS) is a physiological regulatory network that maintains the body’s homeostasis. It controls pain perception, mood, sleep, appetite, immune response, and many other processes through cannabinoid receptors (CB1, CB2), endogenous messenger substances (anandamide, 2-AG), and specific degradation enzymes (FAAH, MAGL).
What are CB1 and CB2 receptors?
CB1 receptors are located primarily in the central nervous system (brain and spinal cord) and control psychoactive and neurological processes. CB2 receptors are found mainly on immune cells and bone and play a central role in regulating inflammation and immune modulation. Both receptor types are activated by the body’s own endocannabinoids as well as by plant cannabinoids such as THC.
Does every human have an endocannabinoid system?
Yes, the endocannabinoid system is present in nearly all vertebrates and is evolutionarily very ancient. It is found in mammals, birds, fish, and even primitive organisms. The basic structure of the ECS is identical in all humans, although genetic variants in receptor genes or enzyme genes can influence individual functionality and thus also the response to cannabinoids.
Can you strengthen the endocannabinoid system?
Yes, there is evidence that lifestyle factors influence ECS activity. Regular physical exercise increases anandamide levels—the so-called „runner’s high“ is at least partly attributable to endocannabinoid release. An omega-3-rich diet provides arachidonic acid precursors from which endocannabinoids are synthesized. Chronic stress, on the other hand, can deplete the ECS. CBD can indirectly increase anandamide levels through FAAH inhibition without direct receptor binding.
Why does THC work on humans?
THC works because it is structurally similar to the body’s own endocannabinoid anandamide and can therefore bind to CB1 and CB2 receptors. Unlike anandamide, however, THC is broken down much more slowly and activates the receptors more intensely and over a longer period. As a result, the natural ECS is stimulated much more strongly than under normal physiological conditions—with the well-known psychoactive and physiological effects as a result.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
